137 related articles for article (PubMed ID: 36070122)
1. MAFLD, patient-centred care, and APASL.
Sarin SK; Eslam M; Fan JG; Lin HC; George J; Omata M
Hepatol Int; 2022 Oct; 16(5):1032-1034. PubMed ID: 36070122
[TBL] [Abstract][Full Text] [Related]
2. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
[TBL] [Abstract][Full Text] [Related]
3. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease].
Shi YW; Xiao QQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275
[TBL] [Abstract][Full Text] [Related]
4. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.
Kawaguchi T; Tsutsumi T; Nakano D; Eslam M; George J; Torimura T
Clin Mol Hepatol; 2022 Apr; 28(2):150-163. PubMed ID: 34753279
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction associated fatty liver disease (MAFLD) and serum vitamin D concentration in South Korea.
Lee HK; Shin SR; Han AL
Asia Pac J Clin Nutr; 2022; 31(2):201-207. PubMed ID: 35766555
[TBL] [Abstract][Full Text] [Related]
6. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
Eslam M; Sarin SK; Wong VW; Fan JG; Kawaguchi T; Ahn SH; Zheng MH; Shiha G; Yilmaz Y; Gani R; Alam S; Dan YY; Kao JH; Hamid S; Cua IH; Chan WK; Payawal D; Tan SS; Tanwandee T; Adams LA; Kumar M; Omata M; George J
Hepatol Int; 2020 Dec; 14(6):889-919. PubMed ID: 33006093
[TBL] [Abstract][Full Text] [Related]
7. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
Nan Y; An J; Bao J; Chen H; Chen Y; Ding H; Dou X; Duan Z; Fan J; Gao Y; Han T; Han Y; Hu P; Huang Y; Huang Y; Jia J; Jiang J; Jiang Y; Li J; Li J; Li R; Li S; Li W; Li Y; Lin S; Liu J; Liu S; Lu L; Lu Q; Luo X; Ma X; Rao H; Ren H; Ren W; Shang J; Shi L; Su M; Wang B; Wang R; Wei L; Wen Z; Wu B; Wu J; Xin S; Xing H; Xu J; Yan M; Yang J; Yang J; Yang L; Yang Y; Yu Y; Zhang L; Zhang L; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhao S; Zheng H; Zhou Y; Zhou Y; Zhuang H; Zuo W; Xu X; Qiao L
J Hepatol; 2021 Aug; 75(2):454-461. PubMed ID: 34019941
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.
Niriella MA; Ediriweera DS; Kasturiratne A; De Silva ST; Dassanayaka AS; De Silva AP; Kato N; Pathmeswaran A; Wickramasinghe AR; de Silva HJ
PLoS One; 2021; 16(2):e0245762. PubMed ID: 33534815
[TBL] [Abstract][Full Text] [Related]
10. Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN).
George J; Lau G; Kawaguchi T; Fan JG; Ji-Dong J; Wang FS; Kumar M; Sarin SK; Omata M; Wong VW; Eslam M
Hepatol Int; 2023 Jun; 17(3):546-549. PubMed ID: 37081251
[No Abstract] [Full Text] [Related]
11. Updates in fatty liver disease: Pathophysiology, diagnosis and management.
Gofton C; George J
Aust J Gen Pract; 2021 Oct; 50(10):702-707. PubMed ID: 34590082
[TBL] [Abstract][Full Text] [Related]
12. From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
Younossi ZM; Rinella ME; Sanyal AJ; Harrison SA; Brunt EM; Goodman Z; Cohen DE; Loomba R
Hepatology; 2021 Mar; 73(3):1194-1198. PubMed ID: 32544255
[TBL] [Abstract][Full Text] [Related]
13. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
Liu Y; Liu S; Huang J; Zhu Y; Lin S
J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
[TBL] [Abstract][Full Text] [Related]
14. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.
Mendez-Sanchez N; Arrese M; Gadano A; Oliveira CP; Fassio E; Arab JP; Chávez-Tapia NC; Dirchwolf M; Torre A; Ridruejo E; Pinchemel-Cotrim H; Castellanos Fernández MI; Uribe M; Girala M; Diaz-Ferrer J; Restrepo JC; Padilla-Machaca M; Dagher L; Gatica M; Olaechea B; Pessôa MG; Silva M
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):65-72. PubMed ID: 33181118
[TBL] [Abstract][Full Text] [Related]
15. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
[TBL] [Abstract][Full Text] [Related]
16. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C.
Al-Omary A; Byth K; Weltman M; George J; Eslam M
J Dig Dis; 2022 Jan; 23(1):33-43. PubMed ID: 34902220
[TBL] [Abstract][Full Text] [Related]
17. The NAFLD-MAFLD debate: Eminence vs evidence.
Fouad Y; Elwakil R; Elsahhar M; Said E; Bazeed S; Ali Gomaa A; Hashim A; Kamal E; Mehrez M; Attia D
Liver Int; 2021 Feb; 41(2):255-260. PubMed ID: 33220154
[TBL] [Abstract][Full Text] [Related]
18. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction.
Gaber Y; AbdAllah M; Salama A; Sayed M; Abdel Alem S; Nafady S
Expert Rev Gastroenterol Hepatol; 2021 Oct; 15(10):1181-1189. PubMed ID: 34263707
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated fatty liver disease - How relevant is this to primary care physicians and diabetologists?
Lee CH
Prim Care Diabetes; 2022 Apr; 16(2):245-251. PubMed ID: 35086794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
